Chou Associates Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ENDP
Endo International plc
ENDP
|
+$11.8M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$7.34M |
| 3 |
Bausch Health
BHC
|
+$5.41M |
| 4 |
SandRidge Energy
SD
|
+$2.15M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPM.WS
JPMorgan Chase
JPM.WS
|
+$23.3M |
| 2 |
Nokia
NOK
|
+$5.03M |
| 3 |
BAC.WS.A
Bank Of America Corporation Ws A
BAC.WS.A
|
+$3.44M |
| 4 |
AstraZeneca
AZN
|
+$711K |
| 5 |
GSK
GSK
|
+$347K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 29.32% |
| 2 | Healthcare | 20.58% |
| 3 | Consumer Discretionary | 10.15% |
| 4 | Technology | 6.3% |
| 5 | Industrials | 2.58% |
Similar funds
Chou Associates Management's Q1 2017 Portfolio in Review
As of Q1 2017, Chou Associates Management held 29 positions worth $301M, down 3.6% from $313M the previous quarter. Its ten largest holdings account for 76% of the portfolio.
Chou Associates Management withdrew a net $11.8M in Q1 2017, closing 2 positions and reducing 3 holdings. Its most notable exit was AstraZeneca, an estimated $711K position sold in full.
By sector, the portfolio is most concentrated in Financials at 29% of assets, up from 29% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Chou Associates Management opened a new position in Endo International plc worth $10.6M.
- Chou Associates Management's largest Q1 2017 buy was Endo International plc: 950,000 shares worth $10.6M.
- Chou Associates Management added most to Bausch Health in Q1 2017, an estimated $5.41M increase.
- Chou Associates Management's biggest Q1 2017 reduction was JPMorgan Chase, cutting an estimated $23.3M.
- Chou Associates Management fully exited AstraZeneca in Q1 2017, selling an estimated $711K.
- Chou Associates Management's ten largest holdings make up 76% of its $301M portfolio in Q1 2017.
- Chou Associates Management opened 2 new positions and closed 2 in Q1 2017.
- Chou Associates Management's portfolio value fell 3.6% quarter-over-quarter to $301M.
Based on Chou Associates Management's 13F filing for Q1 2017, filed 12 May 2017.